Gilead vs Mesoblast, page-31

First 31 Last

Share
Profile

Follow
vasilios

3,804 Posts.

359

18/04/20

10:31

Post #: 44114753
Share

Originally posted by Wazza222: ↑

My understanding of Remestemcel-L in the CV context is that it is for use with critically ill patients who have severe respiratory problems and likely already need a ventilator to survive.
The tests Gilead are doing are on severely ill patients (ie one step before critical). If their drug works,and patients walk out of hospital with no further respiratory complications - then suddenly there is no one in further need of critical care and thus our stem cells. This is where Gileads' drug is a threat to MSB - not that they are competing products but that theirs is preventing the disease progressing to the next stage.
There are still plenty of cases out there who are past the severe stage and hopefully MSB is the go to company to treat them. The recent anecdotal reports about remdesivir are premature to promote any success yet although it is one of these same "leaked glimpses" of the Mt Sinai trial that we are hanging out for ourselves.
@notbrad8 Your attempts to discredit the journalist despite his forthright follow up interview on CNBC seem unjustified. He appeared genuine and did not have to "back track" on the story he presented. He was doing his job - presenting some information that had come his way (a scoop or perhaps deliberately leaked).

Expand

The other way.

MSB Price at posting: $2.17 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

I88

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

29M

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

PH2

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

AGH

Althea Group inks 'JV agreements' to boost marketing of cannabis-based beverage product in US market

There are more pages in this discussion • 244 more messages in this thread...

First 31 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.15		Change -0.003(0.22%)		Mkt cap ! $1.295B

Open	High	Low	Value	Volume
$1.15	$1.16	$1.13	$1.752M	1.533M

Buyers (Bids)

No.	Vol.	Price($)
11	16499	$1.15

Sellers (Offers)

Price($)	Vol.	No.
$1.15	16635	5

View Market Depth

No.	Vol.	Price($)
11	16499	1.145
22	85467	1.140
15	153442	1.135
13	173392	1.130
10	169088	1.125

Price($)	Vol.	No.
1.150	16635	5
1.155	105394	16
1.160	106205	12
1.165	110349	7
1.170	89832	6

Last trade - 13.22pm 22/07/2024 (20 minute delay)

MSB (ASX) Chart

Gilead vs Mesoblast, page-31

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Althea Group inks 'JV agreements' to boost marketing of cannabis-based beverage product in US market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Gilead vs Mesoblast, page-31

Top Stories

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Althea Group inks 'JV agreements' to boost marketing of cannabis-based beverage product in US market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News